More than 3 in 5 children do not receive timely mental health services after firearm injury, study finds

More than three in five children (63%) enrolled in Medicaid do not receive mental health services within six months after a firearm injury, according to a new study published in the journal Pediatrics. In the United States, 11,258 youth experienced nonfatal firearm injuries in 2020. Children who survive firearm injuries are at increased risk for adverse mental health outcomes, such […]

» Read more

Women taking oral estrogen hormones may have increased risk of high blood pressure

Women ages 45 years and older taking estrogen hormone therapy in pill form were more likely to develop high blood pressure than those using transdermal (topical, applied to the skin) or vaginal formulations, according to new research published today in Hypertension, a peer-reviewed American Heart Association journal. A woman’s body produces less estrogen and progesterone after menopause, changes that may […]

» Read more

New British lung cancer drug from AstraZeneca hailed a 'game changer'

New British lung cancer drug from AstraZeneca is hailed as a ‘game changer’ that can HALVE the risk of dying The daily tablets target non-small-cell lung cancer (NSCLC) tumours  Read more: Ground-breaking warhead drug could be cure for lung cancer  A ‘game-changing’ British drug can halve the risk of dying from lung cancer, research has shown. The ground-breaking trial found patients […]

» Read more

Multiple sclerosis: Immune cell invasion enabled by blood-brain barrier breakdown

In a recent study published in the journal Nature Communications, researcher discovered that CD8+ T-cells are detained at the blood-brain barrier (BBB), wherein they contribute to its breakdown and subsequent infiltration of inflammatory cells into the brain. Study: Antigen recognition detains CD8+ T cells at the blood-brain barrier and contributes to its breakdown. Image Credit: Nemes Laszlo / Shutterstock.com Background Multiple sclerosis (MS) is a […]

» Read more

Lupus Therapeutics announces three Phase 3 clinical trials testing new therapies for SLE and lupus nephritis

Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North […]

» Read more

Study finds improved survival in patients with SLE-associated PAH

A team from Peking Union Medical College Hospital in Beijing, China, have explored changes in the characteristics, treatment, and 5-year survival for SLE-associated PAH in the last decade, and possible reasons for survival change. To date, this is the largest multi-center prospective SLE-PAH cohort to describe disease characteristics and prognosis. The results have been shared at the 2023 annual congress […]

» Read more
1 127 128 129 130 131 1,330